Core Viewpoint - Zhijiang Biological announced on an interactive platform that as of September 30, 2025, the total number of shareholders will be 14,435 [2] Summary by Category - **Company Information** - Zhijiang Biological has confirmed that the total number of shareholders is projected to reach 14,435 by September 30, 2025 [2] - **Investor Communication** - The company engaged with investors through an interactive platform, providing transparency regarding shareholder numbers [2]

Core Points - The company, Zhijiang Biology, announced the signing of a "Four-Party Supervision Agreement for Special Fund Storage" on December 9, which involves the establishment of a special fund account at China Merchants Bank for the "Japanese Intelligent Manufacturing Project" [1] Group 1 - The agreement includes the company, its wholly-owned subsidiary Chuan Yue Co., Ltd., China Merchants Bank, and Guotai Junan Securities [1] - The special fund account will be exclusively used for the allocation and utilization of funds related to the investment project [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-068 上海之江生物科技股份有限公司 关于开立募集资金专户并签订募集资金专户监管协 议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 上海之江生物科技股份有限公司（以下简称"公司"）首次公开发行股票并 在科创板上市的注册申请于 2020 年 11 月 27 日经中国证券监督管理委员会同意 注册（证监许可[2020]3214 号《关于同意上海之江生物科技股份有限公司首次 公开发行股票注册的批复》）。公司获准向社会公开发行人民币普通股（A 股） 股票 4,867.6088 万股，每股发行价格人民币 43.22 元，募集资金合计 210,378.05 万元，扣除发行费用后，实际募集资金净额为 194,232.16 万元。上述募集资金 到位情况已经中汇会计师事务所（特殊普通合伙）审验，并由其出具《验资报告》 （中汇会验[2021]第 0039 号）。 二、 募集资金专户的开立情况及《募集资金专户存储四方监管协议》的签 订情况 乙方：招商 ...

Core Viewpoint - The company has successfully raised a total of 2.104 billion yuan through its initial public offering, with a net amount of 1.942 billion yuan allocated for specific projects [1] Fundraising and Management - The company has established a dedicated account at China Merchants Bank for the management of the raised funds, specifically for the "Japan Intelligent Manufacturing Project" [1] - A four-party supervision agreement has been signed among the company, its wholly-owned subsidiary Chuan Yue Co., Ltd., China Merchants Bank, and Guotai Junan Securities to regulate the use of the funds [1] - As of November 28, 2025, the balance in the dedicated account is reported to be 0 USD/0 JPY [1] - The agreement outlines detailed responsibilities, fund usage supervision, and information inquiry protocols among the parties involved [1]

上海之江生物科技股份有限公司 关于 2025 年第三次以集中竞价交易方式回购公司股份 的进展公告 证券代码：688317 证券简称：之江生物 公告编号：2025-067 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，应当在每个月的前 3 个交易日内公告截至上月末 的回购进展情况。现将公司回购股份进展情况公告如下： 2025 年 11 月，公司通过上海证券交易所交易系统以集中竞价交易方式累计 回购公司股份 1,093,704 股，占公司当前总股本 192,157,999 股的比例为 0.57%， 回购成交的最高价为 22.86 元/股，最低价为 21.52 元/股，支付的资金总额为人 民币 24,160,914.13 元（不含印花税、交易佣金等交易费用）。 截至 2025 年 11 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,093,704 股，占公司当前总股本 192, ...

格隆汇12月2日丨之江生物(688317.SH)公布，截至2025年11月28日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购公司股份109.37万股，占公司当前总股本的比例为0.57%，回购成交的最 高价为22.86元/股，最低价为21.52元/股，支付的资金总额为人民币2416.09万元（不含印花税、交易佣 金等交易费用）。 ...

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券代码：688317 证券简称：之江生物 公告编号：2025-066 上海之江生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 25 日（星期二）至 12 月 01 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海之江生物科技 股份有限公司（以下简称"公司"）邮箱 info@liferiver.com.cn 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 02 日（星期二）09:00-10:00 举行 2025 年第三季度业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688317 证券简称：之江生物公告编号：2025-065 上海之江生物科技股份有限公司 关于2025年第三次以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次回购股份符合相关法律法规的规定及公司的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 ■ 一、回购股份的基本情况 2025年10月15日，上海之江生物科技股份有限公司（以下简称"公司"）召开第五届董事会第十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金和股票回 购专项贷款资金通过集中竞价交易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激 励，回购股份价格不超过人民 ...